Conatus Pharmaceuticals Inc. Presents Data Demonstrating Emricasan's Safety Profile at the American Association for Study of Liver Diseases Liver Meeting

Published: Nov 04, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, Nov. 2, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that data from the Phase 1 clinical trial of emricasan, a first-in class, orally active caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death, are being presented at The Liver MeetingĀ®, the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) on November 4, 2013 in Washington, D.C. The Phase 1 clinical trial was conducted to understand the activity of emricasan on caspase activity in healthy subjects.

Help employers find you! Check out all the jobs and post your resume.

Back to news